South Korea
· Delayed Price · Currency is KRW NeoImmuneTech Statistics
Total Valuation
NeoImmuneTech has a market cap or net worth of KRW 21.99 billion. The enterprise value is -14.29 billion.
| Market Cap | 21.99B |
| Enterprise Value | -14.29B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoImmuneTech has 19.77 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 19.77M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.78% |
| Owned by Institutions (%) | 4.79% |
| Float | 14.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 100.79 |
| PB Ratio | 12.06 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.32 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.34 |
Financial Position
The company has a current ratio of 4.12, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.12 |
| Quick Ratio | 3.75 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.10 |
| Interest Coverage | -202.49 |
Financial Efficiency
Return on equity (ROE) is -65.60% and return on invested capital (ROIC) is -39.99%.
| Return on Equity (ROE) | -65.60% |
| Return on Assets (ROA) | -32.40% |
| Return on Capital (ROIC) | -39.99% |
| Revenue Per Employee | 13.30M |
| Profits Per Employee | -536.75M |
| Employee Count | 82 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.91% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.91% |
| 50-Day Moving Average | 1,302.00 |
| 200-Day Moving Average | 1,514.49 |
| Relative Strength Index (RSI) | 39.51 |
| Average Volume (20 Days) | 488,809 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeoImmuneTech had revenue of KRW 1.09 billion and -44.01 billion in losses. Loss per share was -445.18.
| Revenue | 1.09B |
| Gross Profit | 1.09B |
| Operating Income | -45.62B |
| Pretax Income | -44.00B |
| Net Income | -44.01B |
| EBITDA | -42.10B |
| EBIT | -45.62B |
| Loss Per Share | -445.18 |
Balance Sheet
The company has 40.47 billion in cash and 4.19 billion in debt, giving a net cash position of 36.28 billion or 1,834.81 per share.
| Cash & Cash Equivalents | 40.47B |
| Total Debt | 4.19B |
| Net Cash | 36.28B |
| Net Cash Per Share | 1,834.81 |
| Equity (Book Value) | 45.59B |
| Book Value Per Share | 92.22 |
| Working Capital | 34.49B |
Cash Flow
In the last 12 months, operating cash flow was -41.16 billion and capital expenditures -577.56 million, giving a free cash flow of -41.74 billion.
| Operating Cash Flow | -41.16B |
| Capital Expenditures | -577.56M |
| Free Cash Flow | -41.74B |
| FCF Per Share | -2,110.84 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -4,182.03% |
| Pretax Margin | -4,033.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NeoImmuneTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | -40.03% |
| FCF Yield | -189.82% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeoImmuneTech has an Altman Z-Score of -6.28. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.28 |
| Piotroski F-Score | n/a |